Physician profile
Tharun Shetty
NPI 1578595328
$16,798.73
in general payments reported to CMS, 2019-2025
48 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $2,337 · 2021: $2,484 · 2022: $3,020 · 2023: $2,703 · 2024: $1,794 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,911.28 | 2019-2025 | Jardiance, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $1,670.47 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Mannkind Corporation | $1,295.11 | 2022-2025 | Afrezza, V-Go |
| Novo Nordisk INC | $1,184.24 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,122.90 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,106.14 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $939.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $662.52 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $661.15 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $655.12 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Intuity Medical INC | $611.16 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Abbvie INC. | $608.68 | 2021-2024 | Qulipta, Ubrelvy |
| Amgen INC. | $393.78 | 2021-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $332.06 | 2019-2025 | |
| Boston Scientific Corporation | $305.85 | 2020-2023 | Watchman Access System, Watchman Flx |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tharun Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.